DNLI Long Call Strategy

DNLI (Denali Therapeutics Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.

Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatment of Parkinson's disease. The company also develops DNL310 that is in Phase I/II clinical trials for the treatment of hunter syndrome; DNL343, which is in phase 1 clinical trial the treatment of amyotrophic lateral sclerosis (ALS); AR443820/DNL788 completed a phase I clinical trial for the treatment of ALS, multiple sclerosis (MS), and Alzheimer's disease; and SAR443122/DNL758, which is in phase II clinical trial for the treatment of cutaneous lupus erythematosus. It has collaboration agreement with Takeda Pharmaceutical Company, Genentech, Inc., Sanofi, F-star Gamma Limited, F-star Biotechnologische Forschungs-Und Entwicklungsges M.B.H, F-star Biotechnology Limited, SIRION Biotech GmbH, Genzyme Corporation, Harvard University, the Michael J. Fox Foundation, and Centogene; and a research and option agreement with Secarna Pharmaceuticals GmbH & Co. KG. to develop antisense therapies in the field of neurodegenerative diseases.

DNLI (Denali Therapeutics Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $3.14B, a beta of 0.99 versus the broader market, a 52-week range of 12.58-23.77, average daily share volume of 1.7M, a public-listing history dating back to 2017, approximately 443 full-time employees. These structural characteristics shape how DNLI stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.

A beta of 0.99 places DNLI roughly in line with broader market moves, so the strategy payoff and realized volatility track the index-equivalent baseline.

What is a long call on DNLI?

A long call buys upside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes above the strike plus premium at expiration.

Current DNLI snapshot

As of May 15, 2026, spot at $18.72, ATM IV 67.60%, IV rank 12.22%, expected move 19.38%. The long call on DNLI below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 34-day expiry.

Why this long call structure on DNLI specifically: DNLI IV at 67.60% is on the cheap side of its 1-year range, which favors premium-buying structures like a DNLI long call, with a market-implied 1-standard-deviation move of approximately 19.38% (roughly $3.63 on the underlying). The 34-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated DNLI expiries trade a higher absolute premium for lower per-day decay. Position sizing on DNLI should anchor to the underlying notional of $18.72 per share and to the trader's directional view on DNLI stock.

DNLI long call setup

The DNLI long call below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With DNLI near $18.72, the first option leg uses a $18.72 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed DNLI chain at a 34-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 DNLI shares for the stock leg in covered calls and collars).

ActionTypeStrike / BasisPremium (est)
Buy 1Call$18.72N/A

DNLI long call risk and reward

Net Premium / Debit
N/A
Max Profit (per contract)
Unbounded
Max Loss (per contract)
Unbounded
Breakeven(s)
None on modeled curve
Risk / Reward Ratio
N/A

Max profit is unbounded; max loss equals the premium paid times 100. Breakeven is strike plus premium.

DNLI long call payoff curve

Modeled P&L at expiration across a range of underlying prices for the long call on DNLI. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.

When traders use long call on DNLI

Long calls on DNLI express a bullish thesis with defined risk; traders use them ahead of DNLI catalysts (earnings, product launches, macro events) when the expected upside justifies the premium and theta decay.

DNLI thesis for this long call

The market-implied 1-standard-deviation range for DNLI extends from approximately $15.09 on the downside to $22.35 on the upside. A DNLI long call expresses a directional view that the underlying closes above the strike plus premium at expiration, ideally with implied volatility holding or expanding to preserve extrinsic value through the hold period. Current DNLI IV rank near 12.22% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on DNLI at 67.60%. As a Healthcare name, DNLI options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to DNLI-specific events.

DNLI long call positions are structurally bullish; the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. DNLI positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move DNLI alongside the broader basket even when DNLI-specific fundamentals are unchanged. Long-premium structures like a long call on DNLI are particularly exposed to IV-crush risk through scheduled events (earnings, FDA decisions, central-bank meetings) where IV typically contracts post-event regardless of the directional outcome. Always rebuild the position from current DNLI chain quotes before placing a trade.

Frequently asked questions

What is a long call on DNLI?
A long call on DNLI is the long call strategy applied to DNLI (stock). The strategy is structurally bullish: A long call buys upside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes above the strike plus premium at expiration. With DNLI stock trading near $18.72, the strikes shown on this page are snapped to the nearest listed DNLI chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
How are DNLI long call max profit and max loss calculated?
Max profit is unbounded; max loss equals the premium paid times 100. Breakeven is strike plus premium. For the DNLI long call priced from the end-of-day chain at a 30-day expiry (ATM IV 67.60%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
What is the breakeven for a DNLI long call?
The breakeven for the DNLI long call priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current DNLI market-implied 1-standard-deviation expected move is approximately 19.38%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
When should you consider a long call on DNLI?
Long calls on DNLI express a bullish thesis with defined risk; traders use them ahead of DNLI catalysts (earnings, product launches, macro events) when the expected upside justifies the premium and theta decay.
How does current DNLI implied volatility affect this long call?
DNLI ATM IV is at 67.60% with IV rank near 12.22%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.

Related DNLI analysis